methotrexate has been researched along with Benign Monoclonal Gammopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, T; Fujita, Y; Matsumoto, H; Matsuoka, N; Migita, K; Ohkawara, H; Saito, K; Sato, S; Sumichika, Y; Temmoku, J; Watanabe, H; Yashiro-Furuya, M; Yoshida, S | 1 |
| Chiarolanza, I; Di Lernia, V; Ficarelli, E; Lallas, A; Possemato, N; Salvarani, C | 1 |
2 other study(ies) available for methotrexate and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Refractory adult-onset Still's disease complicated with monoclonal gammopathy of undetermined significance: A case report.
Topics: Cytokines; Exanthema; Humans; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Still's Disease, Adult-Onset | 2022 |
Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study.
Topics: Acitretin; Adalimumab; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cross-Sectional Studies; Cyclosporine; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Keratolytic Agents; Male; Methotrexate; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Prevalence; Psoriasis; Tumor Necrosis Factor-alpha | 2015 |